Zurich, Swizerland (ots) - Recently, Solianis successfully finalized a series of tests during which patients with diabetes have worn its multisensor device for non-invasive glucose monitoring at home and at work in the office. The results of these real-life tests as well as earlier tests in a more controlled environment have encouraged Solianis to set up the final device and prepare the market introduction for 2010. ...
New gonadotrophin-releasing hormone (GnRH) receptor antagonist demonstrates rapid, long-term suppression of testosterone Saint-Prex (ots) - Ferring Pharmaceuticals announced today that it has received marketing authorisation from the European Commission, for FIRMAGON® (degarelix), a new GnRH receptor antagonist ...
DNArtistic and Inneova Corporation Limit
Geneva (ots) - Swiss-based www.dnartistic.com 's first piece of DNA luxury jewellery will be sold at 1 million CHF and some of the proceeds will be used to finance the anti-aging services and life extension research of sister company www.inneova.com. Dr. Ivan de Weber, a young Swiss scientist specialized in molecular genetics of aging and co-founder of both Inneova and DNArtistic has brought together a group of ...
Zurich (ots) - Solianis has just finalized a test series in which patients with diabetes have worn the first configuration of the multisensor system for non-invasive Continuous Glucose Monitoring at home and at work. Results show that the system tracks glucose in these settings and that it is sensitive to hyper- ...
Lausanne (ots) - - Gene Signal International, a biotech company registered in Switzerland, will move its headquarter to the EPFL, in Lausanne, - Gene Signal is addressing various issues related to neovascularisation, - Gene Signal is working on a portfolio of ophthalmologic indications, with one now in Phase III trials - Gene Signal ...
Berne (ots) - Swiss hospital standards are in demand abroad. In collaboration with an Indian company, Sonnenhof Swiss Health Ltd (SSH) introduces a new service offering for leading Indian hospitals with the aim of their attaining Swiss quality assurance standards. The cooperation of Hexel and SSH is based on a combination of strengths. SSH - an associated company of the Sonnenhof hospitals in Bern - can draw on ...
Zurich, (ots) - Solianis' multisensor system for non-invasive Continuous Glucose Monitoring is currently being tested by diabetic patients in the home and work environment. 12 patients have completed a 10-day trial aimed at assessing system reliability. Results indicate that the system tracks glucose in home-use settings and is sensitive to hypoglycemic glucose ...
Berlin (ots) - The new compounds will provide a "full time" protection of neurons against aging and degeneration. Continuous administration technologies, which are one of the core competencies of Axxonis Pharma AG, will additionally enable the concept of 24 hours protection. This is a completely new and innovative approach in radical scavenging therapy and in ...
Kaiseraugst (ots) - A new scientific study has shown that consuming beta-carotene over a long period of time may help to preserve mental fitness by improving how the brain, and more importantly the memory, works. While it has long been acknowledged that eating beta-carotene-rich foods or taking supplements of this antioxidant can help to protect the skin from ...
New data on the mechanism of action of the second generation 5-HT3 antagonist palonosetron presented today at the 33rd ESMO Congress in Stockholm, Sweden Stockholm, Sweden (ots) - New data presented today at the 33rd ESMO (European Society of Medical Oncology) Congress in Stockholm may contribute to explain the reason why palonosetron, a second generation 5-HT3 ...
Dittingen, Switzerland (ots) - Throughout recent times, consumer tastes have been honed to enjoy a wide variety of quality bread products. But manufacturers are posed with an escalating dilemma - how to counteract the ever-rising ingredient prices with cost-effective alternatives that ensure bread improvement. With bread remaining an important element in daily diets ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - The 33rd ESMO Congress in Stockholm, the premier European congress in Oncology, serves as a meeting place for medical oncologists, as well as a focal point to exchange ideas with colleagues from other disciplines. The Congress Centre will be the venue for interdisciplinary interaction, a teaching ground, and a place to discuss critical issues for European oncology such as cancer research in Europe, the ...
Zurich (ots) - Solianis' new patents cover the basic technology to monitor changes in the hydration of skin at different depths and to evaluate the impact of cosmetic products: "Device and method for determining at least one characterizing parameter of multilayer body tissue" and "Method and device for ...
Dublin, Ireland (ots) - Helsinn is pleased to announce that Helsinn Birex Pharmaceuticals, its drug facility in Dublin Ireland, has undergone a successful inspection by the US Food and Drug Administration (FDA) without any Form 483 observations. The FDA visit, which lasted 5 days, was a pre-approval inspection ...
Lugano (ots) - Helsinn's Top Management and its U.S. partner Eisai Inc. today announced the availability in the USA of ALOXI® (palonosetron hydrochloride) injection 0.075 mg for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. The introduction of ALOXI® for PONV ...
Zurich (ots) - Solianis is conducting a study in which patients with diabetes are testing a preliminary functional model of the future device for non-invasive glucose monitoring. First results confirm the expected applicability of the multisensor platform in everyday life. Solianis' unique multisensor platform offers an easy and reliable monitoring of changes ...
Kaiseraugst (ots) - If "an apple a day keeps the doctor away", a carrot a day might help to keep the sun burn away. That is the conclusion of a recently published analysis by Professors Wolfgang Köpcke and Jean Krutmann, of Münster University Hospital and the Institut für Umweltmedizinische Forschung in Düsseldorf, Germany, respectively. In a paper ...
Basel (ots) - Herring sandwich? Mackerel soufflé? Salmon fondue? If these items don't form part of your diet, you might be missing out on something. That something is long-chain Omega-3 polyunsaturated fatty acids, a substance vital to good health which is found primarily in oily fish. Consumed regularly, Omega-3 can help in the battle against a variety of ...
Appenzell (ots) - Ergonex Pharma today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe. "The ...
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, together with its partner EISAI Corporation of North America and EISAI's U.S. subsidiary, MGI Pharma, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi® (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for ...
Zürich (ots) - Solianis sees its Multi-Sensor Technology as a promising approach to continuous non-invasive glucose monitoring. Professor Marc Donath, member of the Solianis Scientific Advisory Board and Professor for endocrinology and diabetology at the University Hospital in Zürich, Switzerland, has ...
Volketswil-Zurich (ots) - Juvena of Switzerland, a Swiss cosmetics company established in 1954, launched its Juvedical renewing serum in 2004, thus attracting an ever-growing fan base. Consumers love the product, and express their enthusiasm in letters and emails, which the company receives daily. Physicians and scientists-as well as 15 international awards-confirm ...
Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...
Indianapolis (ots/PRNewswire) - - Global contest seeks expressions of the triumphs and challenges of living with diabetes through art, essay, poetry, photography and music Eli Lilly and Company, the International Diabetes Federation (IDF), and the International Society for Pediatric and ...
Geneva (ots/PRNewswire) - Acrongenomics, Inc. (OTC: AGNM) is pleased to announce that they have acquired a 10.9% interest in Molecular Vision Limited, on a fully diluted basis. The cash consideration will be used by Molecular Vision for working capital and to further develop its technology. Molecular Vision is developing low cost easy-to-use credit-card sized devices for medical testing that will greatly extend ...
San Antonio, Texas (ots/PRNewswire) - - New Findings From a Second Pivotal Phase 3 Study Show Subjects Receiving Ustekinumab Every 12 weeks Maintained Improvement From Psoriasis Through One Year One-year data from the second double blind, placebo-controlled Phase 3 study PHOENIX 1 showed therapy with ...
Basel, Switzerland (ots/PRNewswire) - - Many More Patients Can Now Benefit From Oral Chemotherapy That Significantly Reduces Treatment Time Roche announced today that the European Commission has approved its oral chemotherapy Xeloda (capecitabine) for the treatment of metastatic colorectal cancer in combination with any chemotherapy in all lines of ...
Abbott Park, Illinois (ots/PRNewswire) - - Improved Medical Benefit Rating Granted for XIENCE V from French Health Authority Abbott (NYSE: ABT) today announced that it has received reimbursement approval in France for its XIENCE(TM) V Everolimus Eluting Coronary Stent System, the first drug eluting stent to demonstrate clinical superiority over another drug ...
Maidenhead, England (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the European Medicines Agency (EMEA) has validated the marketing authorisation application for Torisel(R) (temsirolimus) for treating relapsed and/or refractory mantle cell lymphoma (MCL), a rare type of non-Hodgkin's lymphoma (NHL) that accounts for ...